An orally bioavailable, cyclopamine-derived inhibitor of the Hedgehog (Hh) pathway with potential antineoplastic activity. Specifically, Hedgehog pathway inhibitor IPI-926 binds to and inhibits the cell membrane-spanning G-protein coupled receptor SMO, which may result in the suppression of Hh pathway signalling and a decrease in tumour cell proliferation and survival. SMO is activated upon binding of Hh ligand to the cell surface receptor Patched (PTCH); inappropriate activation of Hh signalling and uncontrolled cellular proliferation may be associated with SMO mutations. The Hh signalling pathway plays an important role in proliferation of neuronal precursor cells in the developing cerebellum and other tissues.